Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 May;38(5):573-7.
doi: 10.1097/00004583-199905000-00019.

Absence of cardiovascular adverse effects of sertraline in children and adolescents

T E Wilens  1 , J Biederman, J S March, R Wolkow, C S Fine, R B Millstein, S V Faraone, D Geller, T J Spencer
Affiliations
Clinical Trial

Absence of cardiovascular adverse effects of sertraline in children and adolescents

T E Wilens et al. J Am Acad Child Adolesc Psychiatry. 1999 May.

Abstract

Objective: In a 12 week, placebo-controlled, parallel-design, multicenter study of sertraline for obsessive-compulsive disorder in 107 children and 80 adolescents, the authors prospectively assessed cardiovascular effects to doses of sertraline of < or = 200 mg/day.

Method: Vital signs (blood pressure and heart rate) and electrocardiograph parameters (ECGs) were systematically evaluated at baseline and again throughout treatment.

Results: There were no clinically significant cardiovascular adverse events in any of the subjects enrolled in the study. Moreover, compared with baseline and placebo, sertraline treatment at an average dose of 167 mg did not result in any clinically meaningful changes in any ECG indices (PR, QRS, and QTc intervals), cardiac rhythm, blood pressure, or heart rate.

Conclusions: These prospectively derived results support the cardiovascular safety of sertraline at doses up to 200 mg in children and adolescents.

PubMed Disclaimer

Publication types